2023年的ChEMBL数据库:一个跨越多种生物活性数据类型和时间段的药物发现平台
Barbara Zdrazil1, Eloy Felix1, Fiona Hunter1
1European Molecular Biology Laboratory, European Bioinformatics Institute (EMBL-EBI), Wellcome Genome Campus, Hinxton, Cambridgeshire CB10 1SD, UK.
Nucleic acids research
|November 7, 2023
概括
现在,ChEMBL数据库提供了更多的存储生物活性数据,而不是从文献中提取的数据. 最近的更新包括化学探针数据,抗SARS-CoV-2查结果,以及天然产品和化学探针的新功能.
科学领域:
- 药物发现和化学信息学
- 生物医学数据资源是生物医学数据资源.
- 生物活性分子数据库.
背景情况:
- ChEMBL是一个全面的,开放式的生物活性分子数据库.
- 该数据库自2009年成立以来,其规模和数据多样性大幅扩大.
- 之前的描述已在2012年,2014年,2017年和2019年的核酸研究数据库问题中发表.
研究的目的:
- 详细介绍最近对ChEMBL数据库的更新和增强.
- 要突出存储数据和专业数据集的日益增加的纳入.
- 展示新的功能,提高药物发现的数据实用性.
主要方法:
- 手动策划和从科学文献和存储者中提取数据.
- 整合新的数据集,包括化学探测和专利生物活性数据.
- 开发和实施新的功能,如自然产品相似性得分和行动类型注释.
主要成果:
- BL第27版包括针对抗SARS-CoV-2查和药物重新定位的精选数据.
- 与文献中提取的数据相比,存储的数据现在占生物活性信息的比例更大.
- 新功能增强了生物活性分子的识别和表征,包括化学探针和天然产品.
结论:
- BL数据库继续发展,成为药物发现的关键资源.
- 定期更新和新功能提高了生物活性分子数据的可访问性和实用性.
- 该数据库支持传染病 (例如,SARS-CoV-2) 和天然产品化学等领域的研究.
相关概念视频
Drug Discovery: Overview
8.0K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
8.0K
Structure-Activity Relationships and Drug Design
734
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
734
Drug Biotransformation: Overview
2.4K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.4K
Ligand Binding Sites
12.9K
Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
12.9K
Targets for Drug Action: Overview
6.3K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
6.3K
Cholinergic Antagonists: Chemistry and Structure-Activity Relationship
2.3K
Cholinergic antagonists bind to cholinergic receptors and limit the effects of acetylcholine and other cholinergic agonists. Based on the specific cholinergic receptor affinity, these antagonists are classified as muscarinic or nicotinic. Anticholinergics interrupt parasympathetic innervations while sympathetic innervations remain uninterrupted. Muscarinic antagonists are also called 'muscarinic antagonists', 'antimuscarinics', or 'parasympatholytics'. Nicotinic...
2.3K


